Clinical Images Journal Indexed in PubMed
  • contact@literaturepublishers.org
  • Whitley Bay, NE26 2HU, England, UK
  • Submit Manuscript
Article Details

Case Report

Volume 5, Issue 5 (May Issue)

Successful Use of Anti-PD-1 Antibody to Treat Multiple Metastatic Carcinomas in a Patient with Xeroderma Pigmentosum: Case Report and Literature Review

Mai Itoyama1*, Akihiro Ohara1, Kazuki Yokoyama1, Shun Yamamoto1, Ken Kato1, Taisuke Mori2, Hiroshi Igaki3, Eiji Nakano4,5, Naoya Yamazaki4, Kuniko Sunami6, Chikako Nishigori5,7 and Yoshitaka Honma1

1Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
2Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan
3Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
4Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
5Department of Dermatology, Kobe University Graduate School of Medicine, Tokyo, Japan
6Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan
7Hyogo Blood Center, Japanese Red Cross, Tokyo, Japan

*Corresponding author: Mai Itoyama, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. E-mail: mitoyama@ncc.go.jp

Received: March 15, 2023; Accepted: March 29, 2023; Published: April 05, 2023

Citation: Itoyama M, Ohara A, Yokoyama K, et al. Successful Use of Anti-PD-1 Antibody to Treat Multiple Metastatic Carcinomas in a Patient with Xeroderma Pigmentosum: Case Report and Literature Review. Clin Image Case Rep J. 2023; 5(3): 312.

Successful Use of Anti-PD-1 Antibody to Treat Multiple Metastatic Carcinomas in a Patient with Xeroderma Pigmentosum: Case Report and Literature Review
Abstract

Xeroderma pigmentosum (XP) is a hereditary photosensitive disease in which skin cancers frequently develop in sun-exposed areas. Several reports on the use of immune checkpoint inhibitor (ICI) therapy in patients with difficult-to-treat XP indicate that ICIs have the potential to improve survival outcomes in these patients. This report describes a Japanese man with XP and multiple systemic metastases of carcinoma in whom ICI therapy achieved a favorable outcome. He was diagnosed with XP at the age of about 30 years. Unresectable distant metastases appeared, despite numerous cryotherapy and excisional procedures for recurrent skin tumors. Irinotecan, 5-fluorouracil, carboplatin, and cetuximab were ineffective. Finally, he was treated with nivolumab, which had a marked therapeutic effect. A literature review revealed 10 cases of XP-related cancer that had responded well to ICI. ICI therapy may be an effective tool in patients with XP and unresectable malignant lesions.

Keyword: Dermatologic oncology; Skin cancer; Head and neck cancer; Xeroderma pigmentosum; Immune checkpoint inhibitor